Curated News
By: NewsRamp Editorial Staff
June 24, 2026
Eckert & Ziegler AGM Approves Higher Dividend for 2025
TLDR
- Eckert & Ziegler SE approved a 29% higher dividend of EUR 0.22 per share, boosting shareholder returns.
- The Annual General Meeting approved the dividend proposal with 55.37% share capital representation and majority votes on all items.
- Eckert & Ziegler's isotope components in nuclear medicine help save lives, advancing healthcare for a better tomorrow.
- The in-person AGM was held next to Eckert & Ziegler's Berlin headquarters, with full details available on their website.
Impact - Why it Matters
This dividend increase signals strong financial health and confidence in Eckert & Ziegler's future, rewarding shareholders while the company continues to advance life-saving nuclear medicine and radiation therapy technologies. For investors, it's a positive indicator of stability and growth in the med-tech sector.
Summary
BERLIN – In a show of confidence in its financial health and future prospects, Eckert & Ziegler SE (ISIN DE0005659700) announced that its Annual General Meeting approved a higher dividend for the 2025 fiscal year. Shareholders will receive EUR 0.22 per share, a significant increase from the previous year's EUR 0.17. The meeting, held as an in-person event near the company's headquarters in Berlin, saw 55.37% of the share capital represented. All agenda items, including the endorsements of the Executive Board and Supervisory Board, were approved by a large majority. The detailed voting results and the CEO’s presentation are available on the Eckert & Ziegler SE website.
Eckert & Ziegler SE, a leading specialist in isotope-related components for nuclear medicine and radiation therapy, employs over 1,000 people. The company provides a comprehensive range of services and products for the radiopharmaceutical industry, from early development to contract manufacturing and distribution. Listed in the TecDAX index of Deutsche Börse, Eckert & Ziegler shares (ISIN DE0005659700) are a key player in the medical technology sector. The dividend increase underscores the company's robust performance and commitment to rewarding shareholders, even as it continues to invest in life-saving innovations. For more details on the company's activities and investor relations, contact Karolin Riehle at karolin.riehle@ezag.de or visit www.ezag.com.
The original release can be viewed on www.newmediawire.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Eckert & Ziegler AGM Approves Higher Dividend for 2025
